|Table of Contents|

The efficacy and safety of maintenance therapy with orelabrutinib in the elderly and infirm patients with CNSL

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 07
Page:
1315-1320
Research Field:
Publishing date:

Info

Title:
The efficacy and safety of maintenance therapy with orelabrutinib in the elderly and infirm patients with CNSL
Author(s):
MA Shanshan; ZHANG Xudong; WANG Wenhua; WANG Yanjie; LIU Donglin; ZHANG Mingzhi
Department of Oncology,First Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000,China.
Keywords:
orelabrutinib; central nervous system lymphoma; maintenance therapy; safety
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.07.026
Abstract:
Objective:To evaluate the efficacy and safety of orelabrutinib-based regimens in the maintenance treatment of the elderly and infirm patients with CNSL.Methods:Eighteen patients with CNSL were included in this retrospective study from January 2015 to April 2022.All patients received the orelabrutinib-based maintenance therapy.Efficacy was evaluated based on investigators' assessment of progression-free survival (PFS).The safety of orelabrutinib-based maintenance regimens has also been evaluated.Results:Of the 11 PCNSL patients received median 5(IQR 2.3~8.5) months maintenance therapy,the 6-month PFS rate and 12-month PFS rate were 63.6%,50.9%,respectively.Of the 7 SCNSL patients received median 7.7(IQR 5~9) months maintenance therapy,the 6-month PFS rate and 12-month PFS rate were 100%,75%,respectively.7 CNSL patients with complete response to induction therapy received median 7.7(IQR 5~9.5)months maintenance therapy,the 6-month PFS rate,12-month PFS rate were both 100%.8 patients experienced grade ≥3 AEs.Conclusion:Orelabrutinib-based maintenance regimens were efficacious and well-tolerated in the elderly and infirm patients with CNSL.This therapy effectively prolongs the PFS and offers a new potential therapeutic strategy for these patients.

References:

［1］CORREIA CE,SCHAFF LR,GROMMES C,et al.Central nervous system lymphoma:approach to diagnosis and treatment ［J］.Cancer J,2020,26(3):241-252.
［2］HOANG-XUAN K,BESSELL E,BROMBERG J,et al.Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients:guidelines from the European Association for Neuro-Oncology［J］.Lancet Oncol,2015,16(7):322-332.
［3］SANTAMBROGIO E,NICOLOSI M,VASSALLO F,et al.Aggressive non-Hodgkin lymphomas:risk factors and treatment of central nervous system recurrence［J］.Expert Rev Hematol,2019,12(9):787-796.
［4］TOMITA N,KODAMA F,KANAMORI H,et al.Secondary central nervous system lymphoma［J］.Int J Hematol,2006,84(2):128-135.
［5］BERNSTEIN SH,UNGER JM,LEBLANC M,et al.Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma:a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group［J］.J Clin Oncol,2009,27(1):114-119.
［6］BAIREY O,SHARGIAN-ALON L,SIEGAL T,et al.Consolidation treatment for primary central nervous system lymphoma:Which modality for whom［J］.Acta Haematol,2021,144(4):389-402.
［7］GROMMES C,PASTORE A,PALASKAS N,et al.Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma［J］.Cancer Discov,2017,7(9):1018-1029.
［8］SOUSSAIN C,CHOQUET S,BLONSKI M,et al.Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma:Final analysis of the phase II "proof-of-concept" iLOC study by the lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network［J］.Eur J Cancer,2019,117:121-130.
［9］LEWIS KL,CHIN CK,MANOS K,et al.Ibrutinib for central nervous system lymphoma:the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience［J］.Br J Haematol,2021,192:1049-1053.
［10］WU JJ,WANG WH,DONG M,et al.Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma:a retrospective study［J］.Invest New Drugs,2022,40(3):650-659.
［11］宋玉琴，邓丽娟，张斌，等.奥布替尼在复发/难治原发或继发中枢神经系统淋巴瘤患者的外周血和脑脊液中药物浓度的初步结果［C］.第二十四届全国临床肿瘤学大会暨2021年CSCO学术年会，2021. SONG YQ,DENG LJ,ZHANG B,et al.Preliminary results of albutinib in peripheral blood and cerebrospinal fluid of patients with recurrent/refractory primary or secondary central nervous system lymphoma［J］.The 24th National Conference on Clinical Oncology and the 2021 CSCO Annual Conference,2021.
［12］ZHU J,MA J.Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)［J］.Chin J Cancer Res,2021,33(3):289-301.
［13］KUITUNEN H,KAPRIO E,KARIHTALA P,et al.Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma［J］.Ann Hematol,2020,99(8):1823-1831.
［14］FREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al.Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］.Actas Dermosifiliogr (Engl Ed),2021,112(1):90-92.
［15］MENDEZ JS,OSTROM QT,GITTLEMAN H,et al.The elderly left behind-changes in survival trends of primary centralnervous system lymphoma over the past four decades ［J］.Neuro Oncol,2018,20(5):687-694.
［16］FRITSCH K,KASENDA B,SCHORB E,et al.High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients(PRIMAIN study)［J］.Leukemia,2017,31(4):846-852.
［17］LANGNER-LEMERCIER S,HOUILLIER C,SOUSSAIN C,et al.Primary CNS lymphoma at first relapse/progression:characteristics,management,and outcome of 256 patients from the French LOC network ［J］.Neuro Oncol,2016,18(9):1297-1303.
［18］BAIREY O,SIEGAL T.The possible role of maintenance treatment for primary central nervous system lymphoma［J］.Blood Rev,2018,32(5):378-386.
［19］GLASS J,WON M,SCHULTZ CJ,et al.Phase I and II study of induction chemotherapy with methotrexate,rituximab,and temozolomide,followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma:NRG oncology RTOG 0227［J］.J Clin Oncol,2016,34(14):1620-1625.
［20］HERVE GHESQUIERES,CAROLINE HOUILLIER,OLIVIER CHINOT,et al.Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL):results of a "proof of concept" phase II study of the French LOC network［J］.Blood,2016,128 (22):785.
［21］OMURO A,CORREA DD,DEANGELIS LM,et al.R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma［J］.Blood,2015,125(9):1403-1410.
［22］FERRERI AJ,RENI M,FOPPOLI M,et al.International Extranodal Lymphoma Study Group (IELSG).High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma:a randomised phase 2 trial［J］.Lancet,2009,374(9700):1512-1520.
［23］WU J,GAO F,WANG W,et al.Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma:a prospective phase II trial［J］.Cancer Biol Med,2021,19(7):1089-1099.

Memo

Memo:
National Natural Science Foundation of China(No.82070210，82170183）；国家自然科学基金项目（编号：82070210，82170183）
Last Update: 2023-02-28